Premium
SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor
Author(s) -
MenaDuran Armando V.,
Togo Summanuna H.,
Bazhenova Lyudmila,
Cervera Jose,
Bethel Kelly,
Senent Maria L.,
Nieva Jorge,
Sanz Guillermo F.,
Sanz Miguel A.,
Saven Alan,
Mustelin Tomas
Publication year - 2005
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2005.05516.x
Subject(s) - bone marrow , medicine , immunohistochemistry , myelodysplastic syndromes , survival analysis , proportional hazards model , protein tyrosine phosphatase , pathology , hematology , clinical significance , international prognostic scoring system , oncology , receptor
Summary Myelodysplastic syndrome (MDS) progresses into acute leukaemia with a variable time course. We analysed 45 newly diagnosed patients and found that the expression of the Src homology 2 domain‐containing tyrosine phosphatase 1 (SHP1) had a significant impact on disease severity, progression and overall prognosis. Global or lineage‐specific loss of SHP1 was observed by immunohistochemistry in bone marrow biopsies of MDS patients who progressed rapidly ( P = 0·0021) and had shorter survival ( P < 0·001). Cox regression analysis demonstrated that SHP1 expression in megakaryocytes had prognostic relevance for time to progression ( P = 0·009) and overall survival ( P = 0·001).